Announcing the first paper of @TheLancetHaem Commission on Adverse Events, with @BiostatGirl & @GitaThanaMD. We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination. https://t.co/3fT4aDeale Thread ⬇️ 🧵

👀 Did you catch the latest episode of The HemOnc Pulse? 🙌 @majorajay, of @CUMedicalSchool, joined @RahulBanerjeeMD, of @fredhutch, for an in-depth discussion on patient-reported outcomes in #lymphoma and other blood cancers. 🎧 Don't miss it! https://t.co/U09KzGD0bx

We got over 300 visitors to our open studio as part of OHNY on Saturday October 18th 2025. Watch Eddie move the poster table while lecturing on each poster-- his presentation is a Tour de Force!

Patient- vs clinician-reported AEs from POLARIX @CaThompsonMD: - symptom incidence & severity much higher as assessed by PROs - sustained improvements in all QOL domains except cog functioning (worse in R-CHOP arm) We must measure PROs in #lymsm trials! https://t.co/i3opsMShRe

Don't forget to check out the latest episodes of The HemOnc Pulse! @majorajay, @GabyHobbs, and @HiraSMian recently hopped on the podcast to discuss the latest updates in #lymphoma, #MPNs, #myeloma, and other blood cancers. 🎧 Catch up here! https://t.co/ejawYEeMs0

Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? https://t.co/rFW0XwVqPT Wonderful to work with Dr Laurie Sehn on this review highlighting our approach to relapsed FL #lymsm @BloodPortfolio @WilmotCancer

Spritz Vibe. Limited Edition. Frosted over & fresh for the season, Spritz Vibe Sparkling Snowball Frost Limited Edition is here! CELSIUS. LIVE. FIT. GO.

CNS penetration of pola @BloodAdvances - 3 pts (1 PCNSL, 2 SCNSL): 2 had CR (although these 2 pts received IT chemo & ibrutinib, respectively) - pola detected in CSF of CNSL & systemic LBCL pts Provocative but unclear about single-agent activity. #lymsm https://t.co/3v0QhFWkmz

Ven/obinu outcomes CLL13/14 - 410 pts, 56% unfit CIRS>6 or GFR<70 - no diff PFS/OS by fitness - AEs not different in fit vs unfit - inferior PFS if <70% ven dose intensity (no diff OS) Would love to see this analysis in non-trial fit/unfit cohort. #lymsm https://t.co/nuXB8uyeUm

ePROs after breast cancer RT - 6 wks after RT, pts w/o severe symptoms by PRO-CTCAE offered to cancel f/u appts - only 15% cancelled - pts who cancelled = ⬇️ breast tenderness & fewer hospitalizations Role for PROs in remote sx monitoring. #bcsm #radonc

cc @CULymphoma @CUHematology @CUMedicalSchool @CUAnschutz @CUCancerCenter

Huge thanks to @RahulBanerjeeMD for the invite to chat about PROs and novel patient-centered domains (like time & financial toxicity) for the @Blood_Cancers podcast: https://t.co/hTfVuxt5uZ We also chat about the @TheLancetHaem Commission on AE Reporting:

Our very own @majorajay was interviewed by @RahulBanerjeeMD for The HemOnc Pulse podcast at @Blood_Cancers about patient-reported outcomes and his latest manuscript on adverse event measurement @TheLancetHaem. #lymsm cc @CUAnschutz @CUCancerCenter

Out now! 🎉 In this episode of The HemOnc Pulse, host @RahulBanerjeeMD (@fredhutch) sits down with @majorajay (@CUMedicalSchool) to discuss patient-reported outcomes in #lymphoma and other blood cancers. 🎧 Listen now! https://t.co/I9AaTF8caV

The SUNMO trial manuscript is now published at @JCO_ASCO! Mosun-Pola is superior to RGemOx in patients with ref/rel LBCL with 3X progression free survival and 2x complete response rates. Only 4% had CRS more than a fever. #lymsm @elizabeth_budde https://t.co/7u02KikJmE

Only a few more @mhfbdenver rehearsals before our musical theater themed Spooktacular show on 11/1! #denver

Happy ASH abstract notification day! Looking forward to all your posters and orals in just a few months. #ASH25 @ASH_hematology

What's going to be different with the new IMWG response criteria? Main changes: - FLC >=10 mg/dL with abnormal ratio takes precedence over urine (but urine is not gone) - No more sCR - Bone marrow to confirm CR can be performed +/- 6 weeks from blood testing. - 24-hour urine at

🔊 HOT OFF THE PRESS!! Effects of an Electronic Patient Reported Outcome Measures (e-PROMs) Program on Symptom Reporting, Use of Healthcare, and Overall Survival in Patients With #Lymphoma: A Multicenter Prospective Study #hematology #VBHC #lymsm #PRO

Welcome to our new @CUHematology faculty Dr. Cassandra Duarte! Dr. Duarte is joining our @CULymphoma program with specialization in aggressive B-cell lymphomas as well as mastocytosis and histiocytic disorders. #lymsm

Childhood cancer survivors face higher mortality after colorectal secondary cancers, with 50% diagnosed before age 40. Our new @JNCI_Now manuscript highlights need for tailored screening guidelines. #onctwitter #survonc https://t.co/iBPTXUPPoP

Community oncologists view palliative care as vital for older adults with AML—yet access is uneven, and hospice policy limits (like 🚫transfusions) remain a barrier. Important implications for policy & training! Grateful to @MazieTsangMD for leading this important work!

“It’s a huge win for patients": Research led by @CUCancerCenter member @mana1981, MD, has contributed to a change that could broaden access to a form of CAR T-cell therapy for lymphoma. My latest story for @CUMedicalSchool at @CUAnschutz. #cucityofhealth https://t.co/tBa5B4POi0